Successful Treatment of Upadacitinib in Prurigo Nodularis: A Case Report and Review of the Literature.

IF 0.7 Q3 MEDICINE, GENERAL & INTERNAL
International Medical Case Reports Journal Pub Date : 2025-05-28 eCollection Date: 2025-01-01 DOI:10.2147/IMCRJ.S514339
Bohui Li, Wo Yao, Ran Diao, Boyun Yang, Yongfang Wang, Ting Li, Liuya Ge, Huiying Wang
{"title":"Successful Treatment of Upadacitinib in Prurigo Nodularis: A Case Report and Review of the Literature.","authors":"Bohui Li, Wo Yao, Ran Diao, Boyun Yang, Yongfang Wang, Ting Li, Liuya Ge, Huiying Wang","doi":"10.2147/IMCRJ.S514339","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Prurigo nodularis (PN), while rare, presents significant clinical challenges due to its diverse pathogenesis and presentation. Effective therapy recommendations for PN remain limited. Upadacitinib, an oral highly selective type 1 Janus-associated kinase (JAK, Intracellular tyrosine kinases that phosphorylate cytokine receptors). Inhibitor plays an excellent role in alleviating itching in atopic dermatitis (AD). This is a report on the treatment of PN with upadacitinib, which offers a new option for refractory PN.</p><p><strong>Case presentation: </strong>We share our successful treatment experience of upadacitinib on a 43-year-old female patient with refractory PN failing to conventional therapies. She showed significant improvement at the follow-up visits and no obvious adverse effects happened. We also reviewed published case reports of PN patients and PN-related review researches and made a comprehensive discussion of the potential mechanism of JAK1 inhibitors in treating PN.</p><p><strong>Conclusion: </strong>Upadacitinib may be a safe and potent alternative for patients with refractory PN.</p>","PeriodicalId":14337,"journal":{"name":"International Medical Case Reports Journal","volume":"18 ","pages":"637-644"},"PeriodicalIF":0.7000,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12127823/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Medical Case Reports Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/IMCRJ.S514339","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Prurigo nodularis (PN), while rare, presents significant clinical challenges due to its diverse pathogenesis and presentation. Effective therapy recommendations for PN remain limited. Upadacitinib, an oral highly selective type 1 Janus-associated kinase (JAK, Intracellular tyrosine kinases that phosphorylate cytokine receptors). Inhibitor plays an excellent role in alleviating itching in atopic dermatitis (AD). This is a report on the treatment of PN with upadacitinib, which offers a new option for refractory PN.

Case presentation: We share our successful treatment experience of upadacitinib on a 43-year-old female patient with refractory PN failing to conventional therapies. She showed significant improvement at the follow-up visits and no obvious adverse effects happened. We also reviewed published case reports of PN patients and PN-related review researches and made a comprehensive discussion of the potential mechanism of JAK1 inhibitors in treating PN.

Conclusion: Upadacitinib may be a safe and potent alternative for patients with refractory PN.

Upadacitinib成功治疗结节性痒疹1例报告及文献复习。
背景:结节性痒疹(PN)虽然罕见,但由于其多样的发病机制和表现形式,给临床带来了重大挑战。有效的PN治疗建议仍然有限。Upadacitinib,口服高选择性1型Janus-associated kinase (JAK,细胞内酪氨酸激酶,磷酸化细胞因子受体)。抑制剂对缓解特应性皮炎(AD)患者的瘙痒有很好的作用。这是一篇关于upadacitinib治疗PN的报道,它为难治性PN提供了一个新的选择。病例介绍:我们分享我们对43岁难治性PN患者常规治疗失败的upadacitinib的成功治疗经验。患者在随访中有明显改善,未发生明显不良反应。我们还回顾了已发表的PN患者病例报告和PN相关的综述研究,全面讨论了JAK1抑制剂治疗PN的潜在机制。结论:Upadacitinib可能是难治性PN患者安全有效的替代方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International Medical Case Reports Journal
International Medical Case Reports Journal MEDICINE, GENERAL & INTERNAL-
CiteScore
1.40
自引率
0.00%
发文量
135
审稿时长
16 weeks
期刊介绍: International Medical Case Reports Journal is an international, peer-reviewed, open access, online journal publishing original case reports from all medical specialties. Submissions should not normally exceed 3,000 words or 4 published pages including figures, diagrams and references. As of 1st April 2019, the International Medical Case Reports Journal will no longer consider meta-analyses for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信